The results were reported Saturday at an American College of Cardiology conference in Washington and prompted some doctors to predict that in the near future, far fewer people will be having the traditional operation.
“It’s going to be very hard to tell a patient that if they need an aortic valve, surgery is going to be their best option,’’ said one of the conference leaders, Dr. Prediman K. Shah of Cedars Sinai Heart Institute in Los Angeles.
A bad aortic valve can stiffen and narrow with age, keeping blood from passing through as it should. Until a few years ago, the only solution was a major operation to open the chest, cut out the bad valve and sew in a new one.
|Medtronic Inc.’s CoreValve is photographed at an American College of Cardiology Conference in Washington on Saturday. (AP-Yonhap)|
That changed in 2011, when Edwards Lifesciences Inc. won federal approval for an expandable valve that could fit in a catheter into a leg artery, be guided to the heart and be placed inside the old valve. Studies showed survival was comparable to or a little better with it than with surgery, but strokes were more common after the catheter approach, making some leery of it.
Earlier this year, a rival device ― Medtronic Inc.’s CoreValve ― was approved for treating people at too high risk to have surgery. The new study tested it in nearly 800 people less sick ― eligible for the operation but still with elevated risks.
One year after treatment, 19 percent of the surgery patients but only 14 percent of those given a CoreValve had died.
Stroke rates also seemed lower, though this was not one of the main results researchers were tracking. After one year, 13 percent of surgery patients and 9 percent of the others had had a stroke.
Two-year follow-up is not complete, but “we are certainly encouraged’’ that trends appear to be continuing, said one of the study’s leaders, Dr. David Adams of New York’s Mount Sinai Hospital.
There were drawbacks to the CoreValve, though ― twice as many patients needed pacemakers afterward. Other complications were a tradeoff ― more vascular problems with the CoreValve but more problems with a fluttering heartbeat called atrial fibrillation among those who had surgery.
Still, several independent experts praised the results.
“It’s a great leap forward’’ for fixing valves through blood vessels, said Dr. David Kandzari of Piedmont Heart Institute in Atlanta.
The study was paid for by Medtronic, and many study leaders consult for Medtronic, Edwards or other heart device makers. Results also were published online by the New England Journal of Medicine.
Doctors say both companies’ artificial valves need more long-term study to see if they hold up as well as the ones implanted surgically, which typically last 20 years. Other firms are also testing catheter-placed valves.